Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.

Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM.

NPJ Breast Cancer. 2019 Apr 16;5:12. doi: 10.1038/s41523-019-0107-9. eCollection 2019.

2.

Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.

Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien AJ, Rosen M.

Hum Reprod. 2017 Oct 1;32(10):2123-2129. doi: 10.1093/humrep/dex276.

PMID:
28938748
3.

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.

Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN.

Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8. Erratum in: Clin Cancer Res. 2018 Feb 15;24(4):985.

4.

Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?

Chien AJ, Rugo HS.

J Clin Oncol. 2017 Sep 20;35(27):3089-3091. doi: 10.1200/JCO.2017.73.5670. Epub 2017 Aug 7. No abstract available.

PMID:
28783451
5.

Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):161. doi: 10.1007/s10549-017-4350-1. No abstract available.

PMID:
28660429
6.

Association between Lithium Use and Melanoma Risk and Mortality: A Population-Based Study.

Asgari MM, Chien AJ, Tsai AL, Fireman B, Quesenberry CP Jr.

J Invest Dermatol. 2017 Oct;137(10):2087-2091. doi: 10.1016/j.jid.2017.06.002. Epub 2017 Jun 17.

7.

Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):151-159. doi: 10.1007/s10549-017-4288-3. Epub 2017 May 13. Erratum in: Breast Cancer Res Treat. 2017 Aug;165(1):161.

PMID:
28503722
8.

Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM.

Clin Breast Cancer. 2017 Jun;17(3):e155-e159. doi: 10.1016/j.clbc.2016.12.008. Epub 2016 Dec 29. No abstract available.

PMID:
28110902
9.

WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.

Brown K, Yang P, Salvador D, Kulikauskas R, Ruohola-Baker H, Robitaille AM, Chien AJ, Moon RT, Sherwood V.

Oncogene. 2017 Jun 1;36(22):3119-3136. doi: 10.1038/onc.2016.450. Epub 2017 Jan 16.

10.

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS.

JAMA Oncol. 2017 Mar 1;3(3):313-319. doi: 10.1001/jamaoncol.2016.3904.

PMID:
27832260
11.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

12.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

13.

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN.

Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13.

PMID:
26875185
14.

HER2-positive breast cancer: is more treatment better?

Rugo HS, Chien AJ.

Lancet Oncol. 2016 Mar;17(3):268-70. doi: 10.1016/S1470-2045(15)00623-3. Epub 2016 Feb 10. No abstract available.

PMID:
26874902
15.

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.

Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP.

Breast Cancer Res Treat. 2015 Aug;153(1):173-81. doi: 10.1007/s10549-015-3511-3. Epub 2015 Jul 25.

PMID:
26208485
16.

Control of the interface between heterotypic cell populations reveals the mechanism of intercellular transfer of signaling proteins.

Kshitiz, Afzal J, Suhail Y, Ahn EH, Goyal R, Hubbi ME, Hussaini Q, Ellison DD, Goyal J, Nacev B, Kim DH, Lee JH, Frankel S, Gray K, Bankoti R, Chien AJ, Levchenko A.

Integr Biol (Camb). 2015 Mar;7(3):364-72.

PMID:
25784457
17.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

18.

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT.

J Clin Invest. 2014 Jul;124(7):2877-90. doi: 10.1172/JCI70156. Epub 2014 May 27.

19.

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, Long GV.

PLoS One. 2014 Apr 14;9(4):e94748. doi: 10.1371/journal.pone.0094748. eCollection 2014.

20.

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM.

J Clin Oncol. 2014 May 10;32(14):1472-9. doi: 10.1200/JCO.2013.52.1161. Epub 2014 Apr 7.

21.

FAM129B is a novel regulator of Wnt/β-catenin signal transduction in melanoma cells.

Conrad W, Major MB, Cleary MA, Ferrer M, Roberts B, Marine S, Chung N, Arthur WT, Moon RT, Berndt JD, Chien AJ.

Version 2. F1000Res. 2013 May 31 [revised 2013 Jan 1];2:134. doi: 10.12688/f1000research.2-134.v2. eCollection 2013.

22.

Protein kinase PKN1 represses Wnt/β-catenin signaling in human melanoma cells.

James RG, Bosch KA, Kulikauskas RM, Yang PT, Robin NC, Toroni RA, Biechele TL, Berndt JD, von Haller PD, Eng JK, Wolf-Yadlin A, Chien AJ, Moon RT.

J Biol Chem. 2013 Nov 29;288(48):34658-70. doi: 10.1074/jbc.M113.500314. Epub 2013 Oct 10.

23.

Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail.

Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon RT, Chien AJ.

PLoS One. 2013 Jul 15;8(7):e69593. doi: 10.1371/journal.pone.0069593. Print 2013.

24.

A rare but revealing sign: necrolytic migratory erythema.

Compton NL, Chien AJ.

Am J Med. 2013 May;126(5):387-9. doi: 10.1016/j.amjmed.2013.01.012. Epub 2013 Mar 12. No abstract available.

PMID:
23477490
25.

Developing safety criteria for introducing new agents into neoadjuvant trials.

DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L.

Clin Cancer Res. 2013 Jun 1;19(11):2817-23. doi: 10.1158/1078-0432.CCR-12-2620. Epub 2013 Mar 7. Review.

26.

WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.

Arensman MD, Kovochich AN, Kulikauskas RM, Lay AR, Yang PT, Li X, Donahue T, Major MB, Moon RT, Chien AJ, Dawson DW.

Oncogene. 2014 Feb 13;33(7):899-908. doi: 10.1038/onc.2013.23. Epub 2013 Feb 18.

27.

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L.

J Clin Oncol. 2012 Dec 20;30(36):4584-6; author reply 4588-9. doi: 10.1200/JCO.2012.44.1022. Epub 2012 Nov 19. No abstract available.

PMID:
23169510
28.

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.

Chien AJ, Rugo HS.

Breast Cancer Res Treat. 2013 Jan;137(1):1-12. doi: 10.1007/s10549-012-2328-6. Epub 2012 Nov 10. Review.

29.

WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis.

Yang PT, Anastas JN, Toroni RA, Shinohara MM, Goodson JM, Bosserhoff AK, Chien AJ, Moon RT.

EMBO Mol Med. 2012 Dec;4(12):1294-307. doi: 10.1002/emmm.201201486. Epub 2012 Nov 6.

30.

Targeting Wnt pathways in disease.

Zimmerman ZF, Moon RT, Chien AJ.

Cold Spring Harb Perspect Biol. 2012 Nov 1;4(11). pii: a008086. doi: 10.1101/cshperspect.a008086. Review.

31.

FAM123A binds to microtubules and inhibits the guanine nucleotide exchange factor ARHGEF2 to decrease actomyosin contractility.

Siesser PF, Motolese M, Walker MP, Goldfarb D, Gewain K, Yan F, Kulikauskas RM, Chien AJ, Wordeman L, Major MB.

Sci Signal. 2012 Sep 4;5(240):ra64. doi: 10.1126/scisignal.2002871.

32.

Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.

Conrad WH, Swift RD, Biechele TL, Kulikauskas RM, Moon RT, Chien AJ.

Cell Cycle. 2012 Oct 15;11(20):3724-30. doi: 10.4161/cc.21645. Epub 2012 Aug 16.

33.

The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.

Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M.

Breast Cancer Res Treat. 2012 Aug;134(3):1327-35. doi: 10.1007/s10549-012-2150-1. Epub 2012 Jul 15.

PMID:
22798157
34.

Germline mutation in MSH6 associated with multiple malignant neoplasms in a patient With Muir-Torre syndrome.

Tavakkol Z, Keller JJ, Furmanczyk PS, Bennett RL, Chien AJ.

J Clin Oncol. 2012 Aug 1;30(22):e195-8. doi: 10.1200/JCO.2011.41.5562. Epub 2012 Jun 25. No abstract available.

PMID:
22734033
35.

Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.

Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, Robin NC, Dawson DW, Moon RT, Chien AJ.

Sci Signal. 2012 Jan 10;5(206):ra3. doi: 10.1126/scisignal.2002274.

36.

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN.

Breast Cancer Res Treat. 2012 Jul;134(1):13-20. doi: 10.1007/s10549-011-1918-z. Epub 2011 Dec 24.

37.

Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers.

White BD, Chien AJ, Dawson DW.

Gastroenterology. 2012 Feb;142(2):219-32. doi: 10.1053/j.gastro.2011.12.001. Epub 2011 Dec 8. Review.

38.

Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer.

Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP.

Cancer. 2012 Mar 15;118(6):1710-7. doi: 10.1002/cncr.26459. Epub 2011 Sep 1.

39.

Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer.

Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP.

Cancer. 2012 Apr 1;118(7):1933-9. doi: 10.1002/cncr.26403. Epub 2011 Aug 17.

40.

Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma.

Biechele TL, Camp ND, Fass DM, Kulikauskas RM, Robin NC, White BD, Taraska CM, Moore EC, Muster J, Karmacharya R, Haggarty SJ, Chien AJ, Moon RT.

Chem Biol. 2010 Nov 24;17(11):1177-82. doi: 10.1016/j.chembiol.2010.08.012.

41.

Re: Specific targeting of Wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol.

Biechele TL, Chien AJ.

Carcinogenesis. 2011 Jan;32(1):120; author reply 121. doi: 10.1093/carcin/bgq217. Epub 2010 Oct 27. No abstract available.

PMID:
20980347
42.

A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers.

Lucero OM, Dawson DW, Moon RT, Chien AJ.

Curr Oncol Rep. 2010 Sep;12(5):314-8. doi: 10.1007/s11912-010-0114-3. Review.

43.

The cardiac safety of trastuzumab in the treatment of breast cancer.

Chien AJ, Rugo HS.

Expert Opin Drug Saf. 2010 Mar;9(2):335-46. doi: 10.1517/14740331003627441. Review.

PMID:
20175700
44.

Wnt and related signaling pathways in melanomagenesis.

Keller JJ, Moon RT, Chien AJ.

Cancers (Basel). 2010 May 26;2(2):1000-12. doi: 10.3390/cancers2021000.

45.

A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.

Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM.

Clin Cancer Res. 2009 Sep 1;15(17):5569-75. doi: 10.1158/1078-0432.CCR-09-0522. Epub 2009 Aug 25.

46.

Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis.

Lai SL, Chien AJ, Moon RT.

Cell Res. 2009 May;19(5):532-45. doi: 10.1038/cr.2009.41. Review.

PMID:
19365405
47.

A Wnt survival guide: from flies to human disease.

Chien AJ, Conrad WH, Moon RT.

J Invest Dermatol. 2009 Jul;129(7):1614-27. doi: 10.1038/jid.2008.445. Epub 2009 Jan 29. Review.

48.

Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.

Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm DL, Moon RT.

Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1193-8. doi: 10.1073/pnas.0811902106. Epub 2009 Jan 14.

49.

Subungual Bowen disease in a patient with epidermodysplasia verruciformis presenting clinically as longitudinal melanonychia.

Stetsenko GY, McFarlane RJ, Chien AJ, Fleckman P, Swanson P, George E, Argenyi ZB.

Am J Dermatopathol. 2008 Dec;30(6):582-5. doi: 10.1097/DAD.0b013e31817e6f0d.

PMID:
19033934
50.

CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Shah KV, Chien AJ, Yee C, Moon RT.

J Invest Dermatol. 2008 Dec;128(12):2870-9. doi: 10.1038/jid.2008.170. Epub 2008 Jun 19.

Supplemental Content

Loading ...
Support Center